Ramya Muddasani, DO, MS

home / authors / ramya-muddasani-do-ms

Articles

Edward Kim, MD;Misako Nagasaka, MD;Terence T. Sio, MD, MS;Sandip Patel, MD;Karen M. Yun, MD;Amanda Herrmann, MD;Jyoti Malhotra, MD, MPH;Erminia Massarelli, MD, PhD, MS;Ramya Muddasani, DO, MS

October 21st 2024

Following a comprehensive debate on the treatment of patients with non–small cell lung cancer, Edward Kim, MD, presents the winning team with the title of victors of this CancerNetwork® Face-Off event.

Treatment Options for Patients with EGFRm: EGFR TKI

Edward Kim, MD;Misako Nagasaka, MD;Terence T. Sio, MD, MS;Sandip Patel, MD;Karen M. Yun, MD;Amanda Herrmann, MD;Jyoti Malhotra, MD, MPH;Erminia Massarelli, MD, PhD, MS;Ramya Muddasani, DO, MS

October 21st 2024

Continuing discussion on the treatment of patients with EGFR-mutated NSCLC, Sandip P. Patel, MD, discusses the role of EGFR TKIs without chemotherapy.

Treatment Options for Patients with EGFRm: EGFR TKI + Chemotherapy

Edward Kim, MD;Misako Nagasaka, MD;Terence T. Sio, MD, MS;Sandip Patel, MD;Karen M. Yun, MD;Amanda Herrmann, MD;Jyoti Malhotra, MD, MPH;Erminia Massarelli, MD, PhD, MS;Ramya Muddasani, DO, MS

October 21st 2024

Focusing on data from the FLAURA2 study, Erminia Massarelli, MD, PhD, MS, outlines the role of EGFR TKI plus chemotherapy for patients with EGFR-mutated NSCLC.

Will Neoadjuvant Therapies Replace Surgery Plus Adjuvant Treatment for Resectable NSCLC?

Edward Kim, MD;Misako Nagasaka, MD;Terence T. Sio, MD, MS;Sandip Patel, MD;Karen M. Yun, MD;Amanda Herrmann, MD;Jyoti Malhotra, MD, MPH;Erminia Massarelli, MD, PhD, MS;Ramya Muddasani, DO, MS

October 21st 2024

Teams from University of California San Diego and City of Hope debate whether neoadjuvant therapies will replace surgery plus adjuvant treatment for patients with resectable NSCLC.

Neoadjuvant Chemoimmunotherapy for Resectable NSCLC

Edward Kim, MD;Misako Nagasaka, MD;Terence T. Sio, MD, MS;Sandip Patel, MD;Karen M. Yun, MD;Amanda Herrmann, MD;Jyoti Malhotra, MD, MPH;Erminia Massarelli, MD, PhD, MS;Ramya Muddasani, DO, MS

October 21st 2024

Karen M. Yun, MD, discusses the role for neoadjuvant chemoimmunotherapy in patients with resectable non–small cell lung cancer.

KRAS Patient Case

Edward Kim, MD;Misako Nagasaka, MD;Terence T. Sio, MD, MS;Sandip Patel, MD;Karen M. Yun, MD;Amanda Herrmann, MD;Jyoti Malhotra, MD, MPH;Erminia Massarelli, MD, PhD, MS;Ramya Muddasani, DO, MS

October 21st 2024

Ramya Muddasani, DO, MS, leads a discussion on the treatment of a patient with metastatic NSCLC with a KRAS G12C mutation, highlighting the utilization of sotorasib and the CodeBreaK 100 trial.

Patient Case: PD-L1 Negative NSCLC

Edward Kim, MD;Misako Nagasaka, MD;Terence T. Sio, MD, MS;Sandip Patel, MD;Karen M. Yun, MD;Amanda Herrmann, MD;Jyoti Malhotra, MD, MPH;Erminia Massarelli, MD, PhD, MS;Ramya Muddasani, DO, MS

October 21st 2024

Sandip P. Patel, MD, reviews the case of a patient with PD-L1–negative NSCLC and discusses treatment practices.

Patient Profile: EGFRm Post-Osimertinib

Edward Kim, MD;Misako Nagasaka, MD;Terence T. Sio, MD, MS;Sandip Patel, MD;Karen M. Yun, MD;Amanda Herrmann, MD;Jyoti Malhotra, MD, MPH;Erminia Massarelli, MD, PhD, MS;Ramya Muddasani, DO, MS

October 21st 2024

Ramya Muddasani, DO, MS, presents the case of a patient with EGFR-mutated NSCLC following osimertinib treatment and shares insights gleaned from the INSIGHT 2 trial.

A Case of Metastatic ROS1 Fusion-Positive NSCLC

Edward Kim, MD;Misako Nagasaka, MD;Terence T. Sio, MD, MS;Sandip Patel, MD;Karen M. Yun, MD;Amanda Herrmann, MD;Jyoti Malhotra, MD, MPH;Erminia Massarelli, MD, PhD, MS;Ramya Muddasani, DO, MS

October 21st 2024

Initiating a conversation on patient cases, Karen Yun, MD, presents the profile of a patient with metastatic ROS1 fusion-positive non–small cell lung cancer.

Where Does the POSEIDON Regimen Fit in the NSCLC Treatment Landscape?

Edward Kim, MD;Misako Nagasaka, MD;Terence T. Sio, MD, MS;Sandip Patel, MD;Karen M. Yun, MD;Amanda Herrmann, MD;Jyoti Malhotra, MD, MPH;Erminia Massarelli, MD, PhD, MS;Ramya Muddasani, DO, MS

October 21st 2024

Jyoti Malhotra, MD, MPH, reviews data from the phase III POSEIDON study evaluating durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for patients with metastatic NSCLC.

CheckMate-9LA: 5-Year Update with Nivolumab + Ipilimumab + Chemotherapy in mNSCLC

Edward Kim, MD;Misako Nagasaka, MD;Terence T. Sio, MD, MS;Sandip Patel, MD;Karen M. Yun, MD;Amanda Herrmann, MD;Jyoti Malhotra, MD, MPH;Erminia Massarelli, MD, PhD, MS;Ramya Muddasani, DO, MS

October 21st 2024

Amanda Herrmann, MD, discusses findings from the 5-year update from CheckMate-9LA investigating nivolumab, ipilimumab, and chemotherapy in patients with metastatic NSCLC.

Advanced ALK-Rearranged NSCLC

Edward Kim, MD;Misako Nagasaka, MD;Terence T. Sio, MD, MS;Sandip Patel, MD;Karen M. Yun, MD;Amanda Herrmann, MD;Jyoti Malhotra, MD, MPH;Erminia Massarelli, MD, PhD, MS;Ramya Muddasani, DO, MS

October 21st 2024

Karen Yun, MD, opens the discussion by presenting data from the ALTA-1L and BRIGHTSTAR studies on advanced ALK-rearranged non–small cell lung cancer.

Lorlatinib vs Crizotinib in Treatment-naïve Advanced ALK+ NSCLC: 5-year PFS and Safety from CROWN

Edward Kim, MD;Misako Nagasaka, MD;Terence T. Sio, MD, MS;Sandip Patel, MD;Karen M. Yun, MD;Amanda Herrmann, MD;Jyoti Malhotra, MD, MPH;Erminia Massarelli, MD, PhD, MS;Ramya Muddasani, DO, MS

October 21st 2024

Erminia Massarelli, MD, PhD, MS, presents 5-year progression-free survival and safety data from the CROWN study comparing lorlatinib with crizotinib in treatment-naïve patients with advanced ALK+ NSCLC.

Introduction of the UCSD vs City of Hope Face-Off

Edward Kim, MD;Misako Nagasaka, MD;Terence T. Sio, MD, MS;Sandip Patel, MD;Karen M. Yun, MD;Amanda Herrmann, MD;Jyoti Malhotra, MD, MPH;Erminia Massarelli, MD, PhD, MS;Ramya Muddasani, DO, MS

October 21st 2024

Edward Kim, MD, introduces a CancerNetwork® Face-Off program in which University of California San Diego and City of Hope will present clinical trial data and discuss treatment practices in non–small cell lung cancer (NSCLC).